ChondroGene's Q2 Revenue Slides 42 Percent as R&D Grows and Losses Swell | GenomeWeb
NEW YORK (GenomeWeb News) – ChondroGene today said that second-quarter revenue slid 42 percent as R&D spending rose by nearly one-third and net losses swelled 160 percent.
 
Total receipts for the three months ended June 30 declined to CA$873,020 ($781,020) from CA$1.5 million year over year. ChondroGene said the current quarter’s results comprise a CA$679,228 amortized one-time payment from Pfizer as part of an R&D alliance penned in 2004 and around CA$194,000 in fee and service revenue.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.